Literature DB >> 35249206

Brain cellular senescence in mouse models of Alzheimer's disease.

Angela O Dorigatti1,2, Ruben Riordan3,4, Zhen Yu3,4, Grace Ross3,4, Rong Wang3,4, Nadjalisse Reynolds-Lallement4,5, Kathy Magnusson4,5, Veronica Galvan6,7,8,9,10,11, Viviana I Perez12,13.   

Abstract

The accumulation of senescent cells contributes to aging pathologies, including neurodegenerative diseases, and its selective removal improves physiological and cognitive function in wild-type mice as well as in Alzheimer's disease (AD) models. AD models recapitulate some, but not all components of disease and do so at different rates. Whether brain cellular senescence is recapitulated in some or all AD models and whether the emergence of cellular senescence in AD mouse models occurs before or after the expected onset of AD-like cognitive deficits in these models are not yet known. The goal of this study was to identify mouse models of AD and AD-related dementias that develop measurable markers of cellular senescence in brain and thus may be useful to study the role of cellular senescence in these conditions. We measured the levels of cellular senescence markers in the brains of P301S(PS19), P301L, hTau, and 3xTg-AD mice that model amyloidopathy and/or tauopathy in AD and related dementias and in wild-type, age-matched control mice for each strain. Expression of cellular senescence markers in brains of transgenic P301L and 3xTg-AD mice was largely indistinguishable from that in WT control age-matched mice. In contrast, markers of cellular senescence were differentially increased in brains of transgenic hTau and P301S(PS19) mice as compared to WT control mice before the onset of AD-like cognitive deficits. Taken together, our data suggest that P301S(PS19) and hTau mice may be useful models for the study of brain cellular senescence in tauopathies including, but not limited to, AD.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Aging; Amyloidopathy; Inflammation; Tauopathies

Mesh:

Substances:

Year:  2022        PMID: 35249206      PMCID: PMC9135905          DOI: 10.1007/s11357-022-00531-5

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.581


  57 in total

Review 1.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

2.  Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Authors:  Zdenek Berger; Hanno Roder; Amanda Hanna; Aaron Carlson; Vijayaraghavan Rangachari; Mei Yue; Zbigniew Wszolek; Karen Ashe; Joshua Knight; Dennis Dickson; Cathy Andorfer; Terrone L Rosenberry; Jada Lewis; Mike Hutton; Christopher Janus
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

3.  Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

Authors:  Yasumasa Yoshiyama; Makoto Higuchi; Bin Zhang; Shu-Ming Huang; Nobuhisa Iwata; Takaomi C Saido; Jun Maeda; Tetsuya Suhara; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2007-02-01       Impact factor: 17.173

4.  The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.

Authors:  Bin Zhang; Jenna Carroll; John Q Trojanowski; Yuemang Yao; Michiyo Iba; Justin S Potuzak; Anne-Marie L Hogan; Sharon X Xie; Carlo Ballatore; Amos B Smith; Virginia M-Y Lee; Kurt R Brunden
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

5.  CNS inflammation and neurodegeneration.

Authors:  Tanuja Chitnis; Howard L Weiner
Journal:  J Clin Invest       Date:  2017-09-05       Impact factor: 14.808

6.  Techniques to Induce and Quantify Cellular Senescence.

Authors:  Nicole Noren Hooten; Michele K Evans
Journal:  J Vis Exp       Date:  2017-05-01       Impact factor: 1.355

7.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

Review 8.  Practical considerations for choosing a mouse model of Alzheimer's disease.

Authors:  Joanna L Jankowsky; Hui Zheng
Journal:  Mol Neurodegener       Date:  2017-12-22       Impact factor: 14.195

Review 9.  Cellular Senescence: A Translational Perspective.

Authors:  James L Kirkland; Tamara Tchkonia
Journal:  EBioMedicine       Date:  2017-04-12       Impact factor: 8.143

10.  Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice.

Authors:  Ramona Belfiore; Alexis Rodin; Eric Ferreira; Ramon Velazquez; Caterina Branca; Antonella Caccamo; Salvatore Oddo
Journal:  Aging Cell       Date:  2018-11-28       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.